Last updated: February 16, 2026
Product Overview
NDC 49702-0227 corresponds to the drug Xyrem (sodium oxybate), manufactured by Jazz Pharmaceuticals. It is approved primarily for treating narcolepsy with cataplexy and has other off-label uses. It is classified as a controlled substance due to its abuse potential.
Market Size and Growth Drivers
The global narcolepsy treatment market was valued at approximately USD 1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030. The key factors include increased diagnosis rates, expanded off-label uses, and advancements in drug formulations.
Market Penetration and Competition
Xyrem holds a dominant position in narcolepsy treatment, commanding approximately 65-70% of the US market share as of 2022. It faces competition from other sleep disorder therapies, such as modafinil and sodium oxybate alternatives like Sunosi (solriamfetol) and Wakix (pitolisant). Generic versions are not available; patent protection extends into the early 2030s.
Pricing Trends and Projections
| Year |
Estimated Wholesale Acquisition Cost (WAC) |
Notes |
| 2022 |
USD 40,000 - USD 45,000 per year |
Price includes standard dosing combined with institutional purchasing discounts. |
| 2023 |
USD 42,000 - USD 47,000 per year |
Slight increase driven by inflation and manufacturing costs. |
| 2024 |
USD 44,000 - USD 50,000 per year |
Further gradual rise; expected to remain stable as competition delays generics. |
| 2025 and beyond |
Stabilize around USD 50,000 per year |
No significant generic competition until at least 2032, barring patent decisions.* |
Price Drivers and Risks
The price stability is influenced by the drug's limited competition, regulatory restrictions, and the drug’s classification as a Schedule III controlled substance. Introduction of generics following patent expiry is likely to cause a notable decrease in prices. Clinical trial outcomes, regulatory changes, or reformulation for abuse deterrence could also impact pricing.
Regulatory and Policy Environment
The FDA approved the drug's patent extension into 2032. The Controlled Substances Act maintains strict dispensing controls, complicating import/export and price reductions. The FDA and DEA regulations tightly control prescribing and distribution, affecting overall market accessibility.
Future Market Outlook
Over the next five years, the market is expected to grow modestly driven by increased awareness, expanded off-label applications, and new formulation development. The absence of generic competition until 2032 suggests price stability or incremental increases unless disruptive policy changes or patents are challenged.
Key Considerations for Stakeholders
- Continued patent enforcement preserves pricing power.
- Patent expiration anticipated around 2032 could lead to price erosion.
- Advances in alternative therapies or abuse-deterrent formulations may alter market dynamics.
- Market access models and regulatory changes remain a significant influence.
Key Takeaways
- NDC 49702-0227 (Xyrem) dominates the narcolepsy treatment market with estimated annual prices around USD 44,000 - USD 50,000 through 2024.
- The drug's market is protected by patent until approximately 2032; generic entry expected thereafter.
- Market growth remains steady, driven by increased diagnosis and off-label uses, absent significant price drops until generics appear.
- Regulatory restrictions limit supply chain flexibility and maintain high prices.
- Market competitors include newer therapies like Sunosi and Wakix, but Xyrem's dominance persists.
FAQs
1. What factors could trigger a significant price decline for Xyrem?
Introduction of generic versions post-2032, regulatory changes, or reformulations that diminish abuse potential.
2. How does Xyrem’s pricing compare to alternative narcolepsy treatments?
Xyrem’s annual cost exceeds USD 40,000, significantly higher than non-controlled medications like modafinil (~USD 1,000 annually), but its efficacy for certain symptoms justifies the premium.
3. What is the potential impact of policy changes on the market?
Loosening of controlled substance regulations could reduce costs but may also impact prescribing volumes and access controls.
4. Are there upcoming clinical trials that could influence pricing or market share?
Current trials focus on abuse-deterrent formulations and new delivery systems. No major shifts anticipated until patent expiration.
5. How does patent extension impact market exclusivity?
Patent extensions into 2032 prolong market exclusivity, delaying generic competition and maintaining high prices.
Sources
[1] IQVIA, 2022 Market Data.
[2] FDA Drug Database, 2023.
[3] Jazz Pharmaceuticals, 2023 Annual Report.
[4] MarketWatch, 2023.
[5] US Patent and Trademark Office, 2023.
